Clinical Trial Update: An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluating the long-term safety of twice-daily Exenatide in adults with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED